Both are GHRH-pathway peptides. Both stimulate your own pituitary rather than replacing its output. That is where the similarity ends — one has adult Phase 3 data and a live FDA approval, the other has a discontinued brand and a compounding market built on top of the gap.
The one-table version
| Sermorelin | Tesamorelin | |
|---|---|---|
| Class | GHRH analog (1–29 fragment) | Stabilized GHRH analog |
| FDA status | Brand (Geref) discontinued 2008; compounded only | Approved 2010 as Egrifta |
| Approved indication | None current (was pediatric GH deficiency) | Excess abdominal fat in HIV-associated lipodystrophy |
| Adult RCT evidence | Thin; largely extrapolated and observational | Phase 3, placebo-controlled, n≈806 pooled |
| Headline finding | IGF-1 elevation, modest body-composition shifts | ~15–18% visceral fat reduction vs. placebo at 26 wks |
| Relative cash cost | Entry-level | Substantially higher |
| Typical use pattern | General GH-axis support, sleep, recovery | Visceral adiposity, metabolic |
The discontinuation nobody explains correctly
Sermorelin had an FDA approval. Geref was on the market and it came off in 2008 — for commercial reasons, not because it failed a safety review or an efficacy standard. Recombinant HGH had eaten the indication and the product was not worth keeping on the shelf.
This matters because of how compounded sermorelin gets framed in both directions. Critics call it an unapproved compounded knockoff. Marketers imply it is equivalent to a currently approved drug. Neither is right. The accurate version: the compounded market is the only sermorelin market that exists, because the brand withdrew for business reasons. There is no premium version being withheld from you.
The commercial-withdrawal story explains why sermorelin is compounded. It does not manufacture adult efficacy data that was never generated. Sermorelin’s original approval was pediatric. Adult use rests on mechanism, IGF-1 response, and observational reporting — a weaker foundation than tesamorelin’s, and worth being honest about.
Where tesamorelin actually earned its approval
Two randomized double-blind placebo-controlled Phase 3 trials in adults with HIV-associated lipodystrophy. In the pooled analysis of roughly 806 participants, daily tesamorelin reduced CT-measured visceral adipose tissue by approximately 15% relative to placebo over 26 weeks. Individual trials ranged wider — the least-squares mean difference was around −19.6% in LIPO-010 and −11.7% in CTR-1011. The trial protocol had defined 8% as the minimum clinically meaningful reduction in advance.
Two caveats that get dropped from most summaries:
- Population specificity. Every registration-quality trial was in HIV-associated lipodystrophy. There is no comparable controlled evidence in people without that condition. Off-label use for general belly fat is an extrapolation, not a demonstrated result.
- It targets visceral fat, not scale weight. The endpoint was CT-measured VAT. This is not a weight-loss drug and does not perform like one.
The pulsatility argument
Both compounds act on the pituitary GHRH receptor and both produce a discrete GH pulse rather than a continuous elevation. Tesamorelin’s short half-life is often cited as an advantage over DAC-modified secretagogues, which produce a sustained GH elevation that overrides the natural nocturnal rhythm instead of working with it.
Whether pulsatility preservation translates into a meaningfully different outcome profile in practice is more asserted than demonstrated. It is a mechanistically reasonable argument, not a proven one.
How to actually choose
If the target is visceral adiposity and you have a clinician willing to discuss off-label use with clear eyes about the evidence gap, tesamorelin is the compound with real data behind it — at a price that reflects that.
If the goal is general GH-axis support, sleep quality, and recovery, sermorelin is the cheaper entry point and the one most telehealth programs lead with. Go in understanding that the adult evidence base is thin and that IGF-1 movement is not the same thing as a clinical outcome.
Both compounds require a licensed clinician’s evaluation and a pharmacy. Telehealth has made that consult straightforward, but it is still a consult — including labs in most reputable programs. Any provider willing to ship you a GHRH analog without baseline bloodwork is telling you something about their standards.
Prescription pathway
Frequently Asked
Tesamorelin, without much argument. It has adult Phase 3 randomized placebo-controlled data and a current FDA approval. Sermorelin’s adult use is largely extrapolated from its old pediatric approval and from observational work, not from large randomized adult trials.
The FDA-approved brand product, Geref, was discontinued in 2008 for commercial reasons rather than safety or efficacy failures. That left compounding as the only sermorelin market. It is not a downgrade from an available brand — there is no brand to downgrade from.
No. Its only FDA indication is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Prescribing it for general visceral adiposity is off-label and rests on the independent clinical judgment of the prescriber.
No, and that is the design intent. Both are GHRH-pathway agents that stimulate the pituitary to release its own growth hormone in pulses. Exogenous HGH overrides that system; these work through it, which is why they are subject to the body’s own negative feedback.
Tesamorelin, generally by a wide margin. Sermorelin is the entry-level compounded GHRH option; tesamorelin carries a branded-product history and a much higher cash price even in compounded form.